Importantly, our in vitro and mouse preclinical findings are supported by human clinical data where increased expression of WAVE2 and ITGB1, and decreased expression levels of miR-29 and DGCR8 correlate with poor disease outcome in human patients with breast cancer tumors. Here, WASF2 is linked to breast cancer.